RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2019 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 par value per share
Symbol
RLMD on Nasdaq
Shares outstanding
73,819,979
Price per share
$4.83
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
7,739,580
Total reported value
$15,541,689
% of total 13F portfolios
0%
Share change
+2,436,423
Value change
+$5,268,377
Number of holders
43
Price from insider filings
$4.83
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Ikarian Capital, LLC 4.8% $7,122,152 3,543,359 Ikarian Capital, LLC 30 Sep 2025
Squadron Capital Management LLC 9.9% +62% $2,572,830 +$973,830 3,298,500 +61% Squadron Capital Management LLC 30 Jun 2025

As of 30 Sep 2025, 43 institutional investors reported holding 7,739,580 shares of RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD). This represents 10% of the company’s total 73,819,979 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD) together control 10% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Ikarian Capital, LLC 2.5% 1,843,060 +4477% 0.84% $3,704,551
Driehaus Capital Management LLC 1% 740,006 0% 0.01% $1,487,412
BOOTHBAY FUND MANAGEMENT, LLC 0.94% 693,236 0.04% $1,393,404
ACADIAN ASSET MANAGEMENT LLC 0.79% 582,543 -6% 0% $1,170,000
BlackRock, Inc. 0.69% 508,000 0% 0% $1,021,080
VANGUARD GROUP INC 0.57% 418,580 +15% 0% $841,346
AdvisorShares Investments LLC 0.55% 403,488 +1.8% 0.13% $811,011
GEODE CAPITAL MANAGEMENT, LLC 0.4% 296,215 -2% 0% $595,533
MARSHALL WACE, LLP 0.37% 272,053 +76% 0% $546,827
DEUTSCHE BANK AG\ 0.3% 224,846 0% 0% $451,940
Corient Private Wealth LLC 0.28% 206,667 0% 0% $402,000
TWO SIGMA INVESTMENTS, LP 0.24% 173,614 +82% 0% $348,964
RENAISSANCE TECHNOLOGIES LLC 0.23% 169,700 +13% 0% $341,097
PARSONS CAPITAL MANAGEMENT INC/RI 0.22% 163,336 0% 0.02% $328,306
RBF Capital, LLC 0.22% 163,261 0% 0.02% $328,155
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.19% 138,424 +110% 0% $278,232
STATE STREET CORP 0.14% 101,820 -4.6% 0% $204,658
MGO ONE SEVEN LLC 0.14% 100,000 0% 0% $201,000
JANE STREET GROUP, LLC 0.12% 85,667 -25% 0% $172,190
UBS Group AG 0.08% 59,785 -67% 0% $120,168
NORTHERN TRUST CORP 0.08% 59,023 -0.92% 0% $118,636
LMR Partners LLP 0.08% 55,600 +0.9% 0% $111,756
SIMPLEX TRADING, LLC 0.07% 53,082 +2087% 0% $106,000
apricus wealth, LLC 0.06% 47,462 0% 0.05% $95,399
TWO SIGMA ADVISERS, LP 0.05% 38,800 +55% 0% $77,988

Institutional Holders of RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 310,462 $1,499,531 +$481,377 $4.83 2
2025 Q3 7,739,580 $15,541,689 +$5,268,377 $2.01 43
2025 Q2 5,303,151 $3,177,608 -$311,771 $0.60 48
2025 Q1 6,219,491 $1,678,348 -$765,361 $0.27 43
2024 Q4 8,399,220 $4,362,562 -$9,886,727 $0.52 48
2024 Q3 12,376,687 $40,240,571 -$3,630,516 $3.24 71
2024 Q2 13,555,167 $40,671,232 -$3,047,997 $3.00 79
2024 Q1 14,295,630 $66,487,069 +$4,418,344 $4.65 90
2023 Q4 13,599,764 $56,297,036 -$3,176,284 $4.14 82
2023 Q3 14,992,668 $44,979,292 -$3,168,105 $3.00 87
2023 Q2 16,099,475 $39,628,054 -$4,049,889 $2.46 90
2023 Q1 17,764,331 $40,141,713 -$4,350,347 $2.26 87
2022 Q4 19,133,718 $66,778,420 -$456,168,727 $3.49 105
2022 Q3 25,741,640 $952,907,631 +$76,728,481 $37.02 128
2022 Q2 24,241,796 $460,359,642 +$33,716,171 $18.99 102
2022 Q1 22,820,905 $615,599,579 +$64,114,052 $26.99 105
2021 Q4 20,728,990 $466,943,248 +$239,286,355 $22.53 89
2021 Q3 10,027,406 $262,813,265 -$4,614,248 $26.21 82
2021 Q2 9,943,981 $318,306,021 +$11,943,018 $32.01 82
2021 Q1 9,525,387 $335,356,371 +$11,917,055 $35.21 78
2020 Q4 9,043,863 $290,109,423 -$48,432,841 $32.07 77
2020 Q3 10,178,263 $382,906,223 -$2,364,350 $37.62 70
2020 Q2 10,506,203 $469,322,081 +$57,833,238 $44.75 73
2020 Q1 9,357,058 $319,169,000 +$94,707,615 $34.11 42
2019 Q4 6,797,455 $265,100,000 +$214,009,957 $39.00 43